IGF2R and non-small cell lung carcinoma: Moreover, EGFR-mutated NSCLC cells with high TROP2 expression developed more rapid resistance to gefitinib therapy through the interaction of TROP2 with insulin-like growth factor 2 receptor (IGF2R), the induction of AKT, and the remodeling of the tumor microenvironment [34].